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Thalassemias are a heterogeneous group of disorders recessively inherited with a genetically determined reduction in the rate of synthesis of one or more types 
of normal hemoglobin (Hb) polypeptide chains. It is the most 
common monogenic disease [1,2]. All over the world, around 
100,000 children are born each year with severe homozygous 
state of thalassemia. Thalassemia belt stretches across the 
African continent, Mediterranean regions, Middle East, Indian 
subcontinent, Southeast Asia, Southern China, and Malaysia [1]. 
In India, over 20 million people have the thalassemia gene. The 
prevalence of β genes varies from 3% to 18% in the north and 
1–3% in the south. Different states of the North Eastern region 
show a variable incidence of HbE varying from 16.2% to 
47.3% [3-5]. A huge migrant tea garden population shows a high 
incidence of HbS [6].
Although the benefits of regular red blood cells transfusions 
in patients are increasingly recognized, this approach also has 
the clinical consequence of iron overload, often presenting as a 
secondary disease among transfusion-dependent patients. Iron 
overload, for a long time, has been considered to be the major cause 
of endocrine abnormalities of β thalassemia and this is supported 
by histological studies of different endocrine glands [7-9].
Growth disturbances are a major clinical feature of untreated 
patients with thalassemia [10]. The increasing mean survival 
age is indicative of the fact that modern therapies are generally 
safe and effective but it is becoming increasingly clear that as 
thalassemic patients approach the age of puberty, many of them 
develop growth retardation [11]. It is generally believed that 
growth retardation is directly related to iron toxicity, especially of 
endocrine glands [12,13].
Primary hypothyroidism that may affect thalassemic patients 
from the second decade of life is mainly due to gland infiltration 
by iron overload. Diabetes mellitus in patients receiving 
hypertransfusion for thalassemia is usually attributed to damage 
to β cells due to iron deposition and has been assumed to be 
the principal cause of insulin deficiency. The insulin resistance 
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has been postulated to be at the level of the liver (due to iron 
deposition), where it may interfere with the insulin’s ability 
to suppress hepatic glucose uptake and also at the level of the 
muscle where iron deposits may decrease the glucose uptake [14].
Studies regarding endocrinopathies in thalassemic children 
in this part of the country are limited. Hence, the present 
study was undertaken to study the endocrinal complications of 
thalassemic children of age group 5–18 years and to find out 
the relationship between serum ferritin level and endocrinal 
complications.
MATERIALS AND METHODS
This was a hospital-based cross-sectional study carried out over 
12 months from June 2017 to –May 2018 in the department of 
pediatrics, of a tertiary care hospital, Assam. The study was 
conducted with approval from the Institutional Ethics Committee. 
All children in the age group 5–18 years attending the department 
of pediatrics, who were diagnosed with transfusion-dependent 
thalassemia (beta-thalassemia major, HbE beta-thalassemia, and 
HbS beta-thalassemia) and fulfilling the inclusion criteria, were 
enrolled. After verifying the records, informed consent was taken 
from the parents and those children who fulfilled the inclusion 
criteria.
Data regarding age, gender, ethnic group, socioeconomic 
status, age at diagnosis, type of hemoglobinopathy, presenting 
clinical features, and duration of chelation therapy were recorded 
in a predesigned pro forma. Detailed clinical examination and 
anthropometry were performed. Blood obtained by venipuncture 
and collected in clot activated vials for serum ferritin (ELISA), 
calcium, alkaline phosphatase, phosphate, thyroid-stimulating 
hormone (TSH) (Immunoradiometric assay) and in fluoride vials 
for random blood sugar, and fasting blood sugar (after 6 h of 
fasting).
We used the following definition to define our cases: Stunting: 
Height was measured by stadiometer by standard method. 
WHO chart for height for age was used as reference standard. 
Height for age between −2 standard deviation (SD) and −3 SD 
was considered moderate stunting and <−3SD was considered 
severe stunting (WHO). Diabetes mellitus: Thalassemic children 
whose random plasma glucose was ≥200 mg/dl (on two separate 
occasions) or fasting plasma glucose was ≥126 mg/dl on two 
occasions were considered diabetic [15]. Hypothyroidism: 
Thalassemic children with TSH > 5.5 m IU/L were considered 
to be having hypothyroidism [16]. Hypogonadism: Absence of 
testicular enlargement in boys, not increasing from 2 ml to more 
than 4 ml as measured by Prader orchidometer (14 years in boys) 
or breast development in girls at an age that is 2–2.5 SD later than 
the population mean (13 years in girls) is hypogonadism [17]. 
Hypocalcemia: Total Serum calcium <9 mg/dl [18]. 
Hyperphosphatemia: Serum phosphorous >5.6 mg/dl (5-11 years), 
>5.4 mg/dl (12-15 years), >4.7 mg/dl (16-18 years) [19].
Data were analyzed using Microsoft Excel 2007. Data were 
presented as mean±SD or percentage. p<0.05 was considered as 
statistically significant. All the statistical analysis was done with a 
95% confidence interval. Statistical significance was tested using 
analysis of variance and unpaired t test.
RESULTS
The present study comprised 70 thalassemic children which were 
beta-thalassemia major (19, 27.14%), HbE beta-thalassemia (44, 
62.86%), and sickle beta-thalassemia (7,10%). Among the study 
population, 58.58% were from lower socioeconomic status and 
41.42% were from the lower middle class. The mean age of the 
children included in the study was 9.77±3.91 years (Table 1) with 
a male: female ratio of 1.33:1.
We found that most of the children had serum ferritin level 
between 1000 and 2000 ng/ml and mean was 2165.64±966.20 ng/ml 
(Table 2). Only 10 (14.29%) thalassemia children were on regular 
chelation (deferasirox). The mean serum ferritin in the thalassemic 
subjects who had not taken iron chelator was 2775.32±933.00 ng/ml 
and was significantly higher than those who had taken iron chelator 
either regularly or irregularly (p<0.001) (Table 3).
In our study, 50% (35) of thalassemic children were stunted 
which was more prominent after 9 years of age. Total 78.57% 
children in 9–12 years and 91.67% children in 13–18 years age 
group were stunted. On the contrary, only 6.25% of children 
between 5 and 8 years were stunted. The mean serum ferritin in 
stunted thalassemic children was 2909.86±820.93 ng/ml while it 
was 1421.43±283.41 ng/ml in normal height thalassemic subjects 
(p<0.001). The current study revealed that 13 out of 40 males 
Table 2: Level of serum ferritin in thalassemic children
Serum ferritin (ng/ml) n (%)
<1000 1 (1.43)
1000–2000 36 (51.43)
>2000 33 (47.14)
Total 70 (100.00)
Mean±SD 2165.64±966.20 
Table 3: Distribution of thalassemic children according to chelation 
therapy and mean serum ferritin level
Chelation 
therapy
n (%) Ferritin 
level (mean±SD)
p-value 
Not taken 31 (44.29) 2775.32±933.00 <0.001
Regularly taken 10 (14.29) 1210.00±237.81
Irregularly taken 29 (41.42) 1843.45±710.26
Total 70 (100.00)
SD: Standard deviation
Table 1: Age distribution of thalassemic children
Age group (in years) n (%)
5–8 32 (45.71)
9–12 14 (20.00)
13–18 24 (34.29)
Total 70 (100.00)
Mean±SD 9.77±3.91 years 
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(32.5%) had delayed puberty and 9 out of 30 females (30%) 
had delayed puberty with a male: female ratio of 1.44:1. Table 4 
compares the mean serum ferritin of thalassemic children (with 
endocrinopathy) and normal thalassemic children.
DISCUSSION
The Northeastern region of India, particularly Assam, is a rich 
reservoir of hemoglobinopathies and thalassemias due to the 
migration of various races over the ages and hence being home 
to an assortment of socio-cultural, linguistic, and ethnically 
diverse people. It has been shown by earlier authors that 
high gene frequency for HbE is prevalent in autochthonous 
inhabitants of Assam, having cultural and linguistic affiliation 
with the population of Southeast Asian countries. Whereas HbS 
is restricted to the tea garden labor communities, a group of 
population brought to Assam by British colonial tea planters from 
Central, Eastern, and Southern India during the mid-19th century.
In the present study, 31 (44.29%) children were not on any 
chelation therapy due to economic and other constraints. In our 
institution, we generally use deferasirox as an iron chelator. Only 
39 (55.71%) were receiving chelation therapy, out of which, 
10 children were on regular chelation therapy and rest 29 children 
were on irregular chelation therapy. Similar observations were found 
by Singhal et al. [20] where 47.6% of the cases were not on chelation 
therapy. Furthermore, Saxena et al. [21] reported in their study that 
only 20% of the patients were taking optimum chelation dose.
In this study, only 1 (1.43%) patient had serum ferritin 
<1000 ng/ml, 36 patients (51.43%) had serum ferritin 
value between 1000 and 2000 ng/ml and 33 (47.14%) had 
serum ferritin value >2000 ng/ml with mean serum ferritin 
2165.64±966.20 ng/ml. The mean serum ferritin in thalassemic 
subjects in the age group of 5–8 years was 1535.94±596.65 ng/ml, 
in 9–12 years was 2557.14±993.90 ng/ml, and in 13–18 years was 
2776.88±853.01 ng/ml. Hence, with the advancement of the age 
of the thalassemic subjects, there was a statistically significant 
increase in mean serum ferritin (p<0.001). We had found that 
mean serum ferritin value was significantly higher in cases who 
had not taken chelation therapy. Similar results were obtained 
in a study by Riaz et al. [22] where mean serum ferritin level 
increased progressively after 9 years of age.
In this study, we found that stunting was more prominent after 
9 years of age with the mean age being 12.06±2.24 years. We 
noticed that the mean serum ferritin level of stunted thalassemic 
children was significantly higher than their counterparts with 
normal height (p<0.001). Similar results were obtained by Hamidah 
et al. [23] where they reported that the prevalence of impaired 
growth velocity among the transfusion dependent pre-pubertal 
thalassemics was 57.7% and short stature was more prevalent in 
those above 10 years old compared to those below 10 years old 
(83.3% and 16.7%, respectively). The mean serum ferritin value 
of the thalassemic children with short stature was higher compared 
to patients with normal height. Similar observations were made 
by Najafipour et al. [9] also. Delayed puberty was seen in 91.67% 
of the cases with the mean age being 14.36±1.09 years. In our 
study, 32.50% males and 30% of females had delayed puberty; 
the mean serum ferritin value of thalassemic patients with delayed 
puberty was higher than in patients with normal puberty. However, 
the difference in the mean serum ferritin level was not statistically 
significant between the two groups. Chhabra and Sodhi [24]
concluded that hypogonadism was the most frequent endocrine 
complication in transfusion-dependent thalassemic children 
and the most common cause is iron overload. This finding is in 
accordance with the results of other investigators like Soliman et 
al. [25] mentioned that delayed puberty was frequent finding both 
in boys and girls with thalassemia. Berkovitch et al. [26] had found 
that 28 out of 33 thalassemia patients achieved normal puberty.
We found that hypothyroidism was present in 22 (31.43%) 
and the mean age of the hypothyroid thalassemic patients was 
10.91±3.26 years. Drema et al. [27] reported hypothyroidism in 
26% of their cases. As serum ferritin is the most widely used test 
for assessment of iron status in thalassemic patients, we found a 
statistically significant difference in mean serum ferritin level between 
euthyroid and hypothyroid groups in our study. Similar reports 
were replicated in studies by Pirinççioğlu et al. [28] and Jaipuria 
et al. [29]. The mean serum ferritin in hypocalcemic thalassemic 
cases was significantly higher (3090.92±814.43 ng/ml) than that in 
normocalcemic thalassemic cases (1618.89±537.41 ng/ml) (p<0.001). 
Joshi and Phatarpekar. [30] found that 37.7% of cases were 
hypocalcemic. We found 2.85% with diabetes mellitus and the 
mean age was 14.50±2.12 years. Sharma et al. [31] reported that 
4.7% of the included patients had diabetes mellitus and there was 
no correlation between the serum ferritin levels of patients with and 
without diabetes. The mean serum ferritin in diabetic thalassemic 
cases was higher than in nondiabetic cases, but it was not statistically 
significant which could be due to immune system activation against 
pancreatic beta cells in addition to chronic iron overload.
Adding to the limitation of this study was the small sample 
size; the study included only 70 children as the study was limited 
to only those thalassemic children who seek services in pediatric 
medicine department of the tertiary care center. The study was 
conducted for a short duration of time. No, follow-up was done as 
the study was cross-sectional.
Table 4: Comparison of mean serum ferritin between thalassemic 
children with endocrinopathy and normal thalassemic children
Variable Mean±SD p-value 
Stunted 2909.86±820.93 <0.001 
Normal height thalassemic 
children 
1421.43±283.41
Delayed puberty 2845±859.40 >0.05 
Normal puberty 2027.50±21.92
Hypothyroid 2806.59±929.57 <0.001 
Euthyroid 1885.75±846.89
Hypocalcemic 3090.92±814.43 <0.001 
Normocalcemic 1618.89±537.41
Diabetic 2772.50±1092.48 >0.05 
Nondiabetic 2147.16±965.63
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CONCLUSION
All thalassemic children should be monitored for detecting 
endocrine abnormalities annually. Proper and regular use of iron 
chelators should be started in all thalassemic children receiving 
blood transfusion for 1 year and if serum ferritin is >1000 ng/ml. 
In our study, the majority of the thalassemic children belonged to 
lower socioeconomic status and were unable to take iron chelators 
regularly due to financial constraint.
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